Clinical trial
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung…
NCT00286169 · Sumitomo Pharma Co., Ltd., Industry · Terminated
Key facts
| NCT number | NCT00286169 |
|---|---|
| Title | Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) |
| Official title | Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer |
| Lead sponsor | Sumitomo Pharma Co., Ltd., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Small-cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Amrubicin Hydrochloride |
| Enrollment | 130 |
| Start date | Apr 1, 2006 |
| First posted | Feb 3, 2006 |
| Last update posted | Apr 12, 2022 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: